By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
An antiviral drug called lamivudine is used to treat viral illnesses like hepatitis B and HIV/AIDS. It is a member of the class of medications known as nucleoside reverse transcriptase inhibitors (NRTIs), which prevent viruses from replicating by inhibiting the reverse transcriptase enzyme.
When treating HIV/AIDS, lamivudine is frequently taken in combination with other drugs. It can also be used to treat chronic hepatitis B virus infection, either by itself or in conjunction with other medications. The drug is offered as a pill and a liquid, and it is normally used once or twice day, as prescribed by a doctor.
Lamivudine can have side effects, like any medicines, albeit not everyone gets them. Headache, nauseousness, diarrhea, and weariness are typical adverse reactions.
Patients taking lamivudine should be constantly watched for any signs of liver damage because it can, in rare instances, cause severe liver problems. Lamivudine is taken by mouth as a tablet or a liquid.
A doctor must decide the lamivudine dose, which is based on body weight. The typical dosage is either 10 mg per kg once day.or 5 milligrammes (mg) per kilogramme (kg) of body weight taken twice daily.
The dose may be increased by the doctor as necessary, but it typically does not exceed 300 mg per day when combined with other HIV medications. Always combine lamivudine with another HIV medication.
Global Lamivudine market accounted for $XX Billion in 2023 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2024 to 2030.
A drug called lamivudine is used to treat HIV-1 and chronic hepatitis B infections. Dovato, a full treatment regimen for HIV-1 infection in people without a history of antiretroviral therapy and without any known or suspected alterations linked to resistance to either dolutegravir or lamivudine, was approved by the U.S.
Food and Drug Administration (FDA) in April.Dolutegravir and lamivudine are both ingredients in Dovato.. A new indication and longer-term safety and efficacy results from the GEMINI 1 and 2 trials were added to the Dovato product labelling in August with FDA approval.
According to a research in the New England Journal of Medicine, lamivudine can effectively cure chronic hepatitis B patients who have cirrhosis or advanced fibrosis that has been verified histologically.For a duration of weeks, participants in the were randomly randomised to either lamivudine or a placebo.
